Global respiratory Market is forecast to Increase $41.3 billion in 2023: Radiant Insights

The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as inflammation, the scarring of lung tissue and excessive production of mucus in the airways. This report focuses on the key therapy area indications of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging.

Request a Free Sample Copy of this Report @ https://www.radiantinsights.com/research/global-respiratory-drugs-market-to-2023/request-sample?utm_source=News&utm_medium=OpenPR&utm_campaign=Jyoti

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the underlying cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. However, over the past decade the treatment of respiratory disorders has developed significantly, with novel and targeted therapies emerging onto the market. The approval of the products Kalydeco and Orkambi, in 2012 and 2014 respectively, gave patients disease-modifying treatment options for CF. Targeted biologics have also emerged such as omalizumab and Nucala for the treatment of asthma.

Overall, 937 products are being actively developed in the respiratory pipeline. The pipelines of asthma, COPD, IPF and CF contain 261, 106, 79 and 131 products, respectively. Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area.

Download Full Research Report of Global Respiratory Drugs Market to 2023 @ https://www.radiantinsights.com/research/global-respiratory-drugs-market-to-2023?utm_source=News&utm_medium=OpenPR&utm_campaign=Jyoti

Scope

- Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
- The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
- There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
- The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
- There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
- Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Read more related reports by Radiant Insights:

• Anti-epileptic Drugs for Pediatrics Industry

https://www.radiantinsights.com/research/global-anti-epileptic-drugs-for-pediatrics-industry-2017

• Irritable Bowel Syndrome Treatment Market

https://www.radiantinsights.com/research/global-irritable-bowel-syndrome-treatment-industry-2017

Reasons to buy

- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.

About Radiant Insights, Inc

Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy. Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience help for delivering excellence in all research projects.

Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036,
San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sale@radiantinsights.com

This release was published on openPR.